Prognostic implications of calculated Apo‐lipoprotein B in patients with ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcome is tied to lower cut‐points
Background Debates still surround using lipoproteins including Apo‐B in risk assessment, management, and prognosis of patients with coronary artery disease. During an acute ST‐segment elevation myocardial infarction, Apo‐B might help to achieve incremental prognostic information. Objective We sought...
Gespeichert in:
| Veröffentlicht in: | Clinical cardiology (Mahwah, N.J.) N.J.), 2021-06, Vol.44 (6), p.824-832 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 832 |
|---|---|
| container_issue | 6 |
| container_start_page | 824 |
| container_title | Clinical cardiology (Mahwah, N.J.) |
| container_volume | 44 |
| creator | Ghodsi, Saeed Mohebi, Mehrnaz Sadre‐Bafghi, Seyed‐Ali Poorhosseini, Hamidreza Salarifar, Mojtaba Alidoosti, Mohammad Haji‐Zeinali, Ali‐Mohammad Amirzadegan, Alireza Aghajani, Hassan Jenab, Yaser Hosseini, Zahra |
| description | Background
Debates still surround using lipoproteins including Apo‐B in risk assessment, management, and prognosis of patients with coronary artery disease. During an acute ST‐segment elevation myocardial infarction, Apo‐B might help to achieve incremental prognostic information.
Objective
We sought to determine the potential prognostic utility of calculated Apo‐B in a cohort of patients with STEMI undergoing primary PCI.
Methods
A retrospective cohort study was conducted enrolling 2,259 patients with a diagnosis of acute STEMI who underwent primary PCI. Apo‐B was obtained using a valid equation based on initial lipid measurements. High Apo‐B was defined as a level of 65 or higher. Primary endpoint of the study was major adverse cardiovascular events (MACE).
Results
Mean age of the participants was 59.54 years and 77.9% of them were male. After a Median follow up of 15 (6.2) months, high Apo‐B was associated with MACE and the OR (95% CI) was 3.02 (1.07–8.47), p = .036. Odds ratios for prediction of MACE pertaining to LVEF, and smoking were 0.97 (p = .044), and 1.07 (p = .033), respectively. However, High Apo‐B was not able to predict suboptimal TIMI flow. Accordingly, the Odds ratio was 0.56 (0.17–1.87), p = 0.349. The power of High LDL‐C and Non‐HDLC for prediction of MACE were assessed in distinct models. Attained odds ratios were [2.40 (0.90–6.36), p = .077] and [1.80 (0.75–4.35), p = 0.191], respectively.
Conclusion
Calculated Apo‐B appears to be a simple tool applicable for prediction of cardiovascular events in patients with STEMI superior to both Non‐HDLC and LDL‐C. |
| doi_str_mv | 10.1002/clc.23610 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8207970</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A710566738</galeid><sourcerecordid>A710566738</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4300-10b5dce019b32fc3aa31ad224b01eda43a94bf87b20cdf195e405f999a759d743</originalsourceid><addsrcrecordid>eNp9ktuKFDEQhhtR3HX1wjcIeKMXM5tD93THC2EcPMHACq7XIZOuns2STtokPcPc-Qg-nE_gk1hzQFlRCSRQ-f6_UpUqiqeMThml_NI4M-Vixui94pxJwSdNLer7xTllMzqRvJFnxaOUbhGlDRcPizMhZMlFKc-L7x9jWPuQsjXE9oOzRmcbfCKhI0Y7MzqdoSXzIfz4-s3ZIQwxZLCevCa4DQiDz4lsbb4hn66RSbDuMUTAweZgRfpdMDq2VjuUdDqaQ3T0LcR1sH5Nhmh7HXdkgGjGrD2EMRETYvD7qPUZ4gYtUfWSXI3ZhB6ITQRTtyQH4sIWIkElZh_QMKfHxYNOuwRPTudF8fntm-vF-8ny6t2HxXw5MaWgdMLoqmoNUCZXgndGaC2YbjkvV5RBq0uhZbnqmnrFqWk7JisoadVJKXVdybYuxUXx6ug7jKse0MrnqJ061aOCturujbc3ah02quG0ljVFg-cngxi-jJCy6m0y4NyxCYpXnLOmaSRD9Nkf6G0Yo8fykKpEyQRj9P9UyfisRug3tdYOFH5KwNeZfWo1R6CazWrRIDX9C4Wrhd6a4KGzGL8jeHEUmBhSitD96gSjaj-oCgdVHQYV2csju0WT3b9BtVgujoqfk6Dwdg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2541267103</pqid></control><display><type>article</type><title>Prognostic implications of calculated Apo‐lipoprotein B in patients with ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcome is tied to lower cut‐points</title><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Ghodsi, Saeed ; Mohebi, Mehrnaz ; Sadre‐Bafghi, Seyed‐Ali ; Poorhosseini, Hamidreza ; Salarifar, Mojtaba ; Alidoosti, Mohammad ; Haji‐Zeinali, Ali‐Mohammad ; Amirzadegan, Alireza ; Aghajani, Hassan ; Jenab, Yaser ; Hosseini, Zahra</creator><creatorcontrib>Ghodsi, Saeed ; Mohebi, Mehrnaz ; Sadre‐Bafghi, Seyed‐Ali ; Poorhosseini, Hamidreza ; Salarifar, Mojtaba ; Alidoosti, Mohammad ; Haji‐Zeinali, Ali‐Mohammad ; Amirzadegan, Alireza ; Aghajani, Hassan ; Jenab, Yaser ; Hosseini, Zahra</creatorcontrib><description>Background
Debates still surround using lipoproteins including Apo‐B in risk assessment, management, and prognosis of patients with coronary artery disease. During an acute ST‐segment elevation myocardial infarction, Apo‐B might help to achieve incremental prognostic information.
Objective
We sought to determine the potential prognostic utility of calculated Apo‐B in a cohort of patients with STEMI undergoing primary PCI.
Methods
A retrospective cohort study was conducted enrolling 2,259 patients with a diagnosis of acute STEMI who underwent primary PCI. Apo‐B was obtained using a valid equation based on initial lipid measurements. High Apo‐B was defined as a level of 65 or higher. Primary endpoint of the study was major adverse cardiovascular events (MACE).
Results
Mean age of the participants was 59.54 years and 77.9% of them were male. After a Median follow up of 15 (6.2) months, high Apo‐B was associated with MACE and the OR (95% CI) was 3.02 (1.07–8.47), p = .036. Odds ratios for prediction of MACE pertaining to LVEF, and smoking were 0.97 (p = .044), and 1.07 (p = .033), respectively. However, High Apo‐B was not able to predict suboptimal TIMI flow. Accordingly, the Odds ratio was 0.56 (0.17–1.87), p = 0.349. The power of High LDL‐C and Non‐HDLC for prediction of MACE were assessed in distinct models. Attained odds ratios were [2.40 (0.90–6.36), p = .077] and [1.80 (0.75–4.35), p = 0.191], respectively.
Conclusion
Calculated Apo‐B appears to be a simple tool applicable for prediction of cardiovascular events in patients with STEMI superior to both Non‐HDLC and LDL‐C.</description><identifier>ISSN: 0160-9289</identifier><identifier>EISSN: 1932-8737</identifier><identifier>DOI: 10.1002/clc.23610</identifier><identifier>PMID: 33942349</identifier><language>eng</language><publisher>New York: Wiley Periodicals, Inc</publisher><subject>Analysis ; Angioplasty ; Apo‐B ; Blood lipids ; Cardiac patients ; Cardiology ; Cardiovascular disease ; Care and treatment ; Cholesterol ; Clinical Investigations ; Clopidogrel ; Coronary vessels ; Heart attack ; Heart attacks ; Kidney diseases ; Lipoproteins ; Low density lipoproteins ; MACE ; Medical research ; Medical treatment ; Medicine, Experimental ; Normal distribution ; Patient outcomes ; Population ; primary PCI ; Prognosis ; revascularization ; Risk assessment ; STEMI ; survival ; Ticagrelor ; Transluminal angioplasty ; Values</subject><ispartof>Clinical cardiology (Mahwah, N.J.), 2021-06, Vol.44 (6), p.824-832</ispartof><rights>2021 The Authors. published by Wiley Periodicals LLC.</rights><rights>COPYRIGHT 2021 John Wiley & Sons, Inc.</rights><rights>2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4300-10b5dce019b32fc3aa31ad224b01eda43a94bf87b20cdf195e405f999a759d743</citedby><cites>FETCH-LOGICAL-c4300-10b5dce019b32fc3aa31ad224b01eda43a94bf87b20cdf195e405f999a759d743</cites><orcidid>0000-0001-5064-9623 ; 0000-0003-0902-217X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207970/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207970/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids></links><search><creatorcontrib>Ghodsi, Saeed</creatorcontrib><creatorcontrib>Mohebi, Mehrnaz</creatorcontrib><creatorcontrib>Sadre‐Bafghi, Seyed‐Ali</creatorcontrib><creatorcontrib>Poorhosseini, Hamidreza</creatorcontrib><creatorcontrib>Salarifar, Mojtaba</creatorcontrib><creatorcontrib>Alidoosti, Mohammad</creatorcontrib><creatorcontrib>Haji‐Zeinali, Ali‐Mohammad</creatorcontrib><creatorcontrib>Amirzadegan, Alireza</creatorcontrib><creatorcontrib>Aghajani, Hassan</creatorcontrib><creatorcontrib>Jenab, Yaser</creatorcontrib><creatorcontrib>Hosseini, Zahra</creatorcontrib><title>Prognostic implications of calculated Apo‐lipoprotein B in patients with ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcome is tied to lower cut‐points</title><title>Clinical cardiology (Mahwah, N.J.)</title><description>Background
Debates still surround using lipoproteins including Apo‐B in risk assessment, management, and prognosis of patients with coronary artery disease. During an acute ST‐segment elevation myocardial infarction, Apo‐B might help to achieve incremental prognostic information.
Objective
We sought to determine the potential prognostic utility of calculated Apo‐B in a cohort of patients with STEMI undergoing primary PCI.
Methods
A retrospective cohort study was conducted enrolling 2,259 patients with a diagnosis of acute STEMI who underwent primary PCI. Apo‐B was obtained using a valid equation based on initial lipid measurements. High Apo‐B was defined as a level of 65 or higher. Primary endpoint of the study was major adverse cardiovascular events (MACE).
Results
Mean age of the participants was 59.54 years and 77.9% of them were male. After a Median follow up of 15 (6.2) months, high Apo‐B was associated with MACE and the OR (95% CI) was 3.02 (1.07–8.47), p = .036. Odds ratios for prediction of MACE pertaining to LVEF, and smoking were 0.97 (p = .044), and 1.07 (p = .033), respectively. However, High Apo‐B was not able to predict suboptimal TIMI flow. Accordingly, the Odds ratio was 0.56 (0.17–1.87), p = 0.349. The power of High LDL‐C and Non‐HDLC for prediction of MACE were assessed in distinct models. Attained odds ratios were [2.40 (0.90–6.36), p = .077] and [1.80 (0.75–4.35), p = 0.191], respectively.
Conclusion
Calculated Apo‐B appears to be a simple tool applicable for prediction of cardiovascular events in patients with STEMI superior to both Non‐HDLC and LDL‐C.</description><subject>Analysis</subject><subject>Angioplasty</subject><subject>Apo‐B</subject><subject>Blood lipids</subject><subject>Cardiac patients</subject><subject>Cardiology</subject><subject>Cardiovascular disease</subject><subject>Care and treatment</subject><subject>Cholesterol</subject><subject>Clinical Investigations</subject><subject>Clopidogrel</subject><subject>Coronary vessels</subject><subject>Heart attack</subject><subject>Heart attacks</subject><subject>Kidney diseases</subject><subject>Lipoproteins</subject><subject>Low density lipoproteins</subject><subject>MACE</subject><subject>Medical research</subject><subject>Medical treatment</subject><subject>Medicine, Experimental</subject><subject>Normal distribution</subject><subject>Patient outcomes</subject><subject>Population</subject><subject>primary PCI</subject><subject>Prognosis</subject><subject>revascularization</subject><subject>Risk assessment</subject><subject>STEMI</subject><subject>survival</subject><subject>Ticagrelor</subject><subject>Transluminal angioplasty</subject><subject>Values</subject><issn>0160-9289</issn><issn>1932-8737</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>BENPR</sourceid><recordid>eNp9ktuKFDEQhhtR3HX1wjcIeKMXM5tD93THC2EcPMHACq7XIZOuns2STtokPcPc-Qg-nE_gk1hzQFlRCSRQ-f6_UpUqiqeMThml_NI4M-Vixui94pxJwSdNLer7xTllMzqRvJFnxaOUbhGlDRcPizMhZMlFKc-L7x9jWPuQsjXE9oOzRmcbfCKhI0Y7MzqdoSXzIfz4-s3ZIQwxZLCevCa4DQiDz4lsbb4hn66RSbDuMUTAweZgRfpdMDq2VjuUdDqaQ3T0LcR1sH5Nhmh7HXdkgGjGrD2EMRETYvD7qPUZ4gYtUfWSXI3ZhB6ITQRTtyQH4sIWIkElZh_QMKfHxYNOuwRPTudF8fntm-vF-8ny6t2HxXw5MaWgdMLoqmoNUCZXgndGaC2YbjkvV5RBq0uhZbnqmnrFqWk7JisoadVJKXVdybYuxUXx6ug7jKse0MrnqJ061aOCturujbc3ah02quG0ljVFg-cngxi-jJCy6m0y4NyxCYpXnLOmaSRD9Nkf6G0Yo8fykKpEyQRj9P9UyfisRug3tdYOFH5KwNeZfWo1R6CazWrRIDX9C4Wrhd6a4KGzGL8jeHEUmBhSitD96gSjaj-oCgdVHQYV2csju0WT3b9BtVgujoqfk6Dwdg</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Ghodsi, Saeed</creator><creator>Mohebi, Mehrnaz</creator><creator>Sadre‐Bafghi, Seyed‐Ali</creator><creator>Poorhosseini, Hamidreza</creator><creator>Salarifar, Mojtaba</creator><creator>Alidoosti, Mohammad</creator><creator>Haji‐Zeinali, Ali‐Mohammad</creator><creator>Amirzadegan, Alireza</creator><creator>Aghajani, Hassan</creator><creator>Jenab, Yaser</creator><creator>Hosseini, Zahra</creator><general>Wiley Periodicals, Inc</general><general>John Wiley & Sons, Inc</general><scope>24P</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5064-9623</orcidid><orcidid>https://orcid.org/0000-0003-0902-217X</orcidid></search><sort><creationdate>202106</creationdate><title>Prognostic implications of calculated Apo‐lipoprotein B in patients with ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcome is tied to lower cut‐points</title><author>Ghodsi, Saeed ; Mohebi, Mehrnaz ; Sadre‐Bafghi, Seyed‐Ali ; Poorhosseini, Hamidreza ; Salarifar, Mojtaba ; Alidoosti, Mohammad ; Haji‐Zeinali, Ali‐Mohammad ; Amirzadegan, Alireza ; Aghajani, Hassan ; Jenab, Yaser ; Hosseini, Zahra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4300-10b5dce019b32fc3aa31ad224b01eda43a94bf87b20cdf195e405f999a759d743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Analysis</topic><topic>Angioplasty</topic><topic>Apo‐B</topic><topic>Blood lipids</topic><topic>Cardiac patients</topic><topic>Cardiology</topic><topic>Cardiovascular disease</topic><topic>Care and treatment</topic><topic>Cholesterol</topic><topic>Clinical Investigations</topic><topic>Clopidogrel</topic><topic>Coronary vessels</topic><topic>Heart attack</topic><topic>Heart attacks</topic><topic>Kidney diseases</topic><topic>Lipoproteins</topic><topic>Low density lipoproteins</topic><topic>MACE</topic><topic>Medical research</topic><topic>Medical treatment</topic><topic>Medicine, Experimental</topic><topic>Normal distribution</topic><topic>Patient outcomes</topic><topic>Population</topic><topic>primary PCI</topic><topic>Prognosis</topic><topic>revascularization</topic><topic>Risk assessment</topic><topic>STEMI</topic><topic>survival</topic><topic>Ticagrelor</topic><topic>Transluminal angioplasty</topic><topic>Values</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghodsi, Saeed</creatorcontrib><creatorcontrib>Mohebi, Mehrnaz</creatorcontrib><creatorcontrib>Sadre‐Bafghi, Seyed‐Ali</creatorcontrib><creatorcontrib>Poorhosseini, Hamidreza</creatorcontrib><creatorcontrib>Salarifar, Mojtaba</creatorcontrib><creatorcontrib>Alidoosti, Mohammad</creatorcontrib><creatorcontrib>Haji‐Zeinali, Ali‐Mohammad</creatorcontrib><creatorcontrib>Amirzadegan, Alireza</creatorcontrib><creatorcontrib>Aghajani, Hassan</creatorcontrib><creatorcontrib>Jenab, Yaser</creatorcontrib><creatorcontrib>Hosseini, Zahra</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cardiology (Mahwah, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghodsi, Saeed</au><au>Mohebi, Mehrnaz</au><au>Sadre‐Bafghi, Seyed‐Ali</au><au>Poorhosseini, Hamidreza</au><au>Salarifar, Mojtaba</au><au>Alidoosti, Mohammad</au><au>Haji‐Zeinali, Ali‐Mohammad</au><au>Amirzadegan, Alireza</au><au>Aghajani, Hassan</au><au>Jenab, Yaser</au><au>Hosseini, Zahra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic implications of calculated Apo‐lipoprotein B in patients with ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcome is tied to lower cut‐points</atitle><jtitle>Clinical cardiology (Mahwah, N.J.)</jtitle><date>2021-06</date><risdate>2021</risdate><volume>44</volume><issue>6</issue><spage>824</spage><epage>832</epage><pages>824-832</pages><issn>0160-9289</issn><eissn>1932-8737</eissn><abstract>Background
Debates still surround using lipoproteins including Apo‐B in risk assessment, management, and prognosis of patients with coronary artery disease. During an acute ST‐segment elevation myocardial infarction, Apo‐B might help to achieve incremental prognostic information.
Objective
We sought to determine the potential prognostic utility of calculated Apo‐B in a cohort of patients with STEMI undergoing primary PCI.
Methods
A retrospective cohort study was conducted enrolling 2,259 patients with a diagnosis of acute STEMI who underwent primary PCI. Apo‐B was obtained using a valid equation based on initial lipid measurements. High Apo‐B was defined as a level of 65 or higher. Primary endpoint of the study was major adverse cardiovascular events (MACE).
Results
Mean age of the participants was 59.54 years and 77.9% of them were male. After a Median follow up of 15 (6.2) months, high Apo‐B was associated with MACE and the OR (95% CI) was 3.02 (1.07–8.47), p = .036. Odds ratios for prediction of MACE pertaining to LVEF, and smoking were 0.97 (p = .044), and 1.07 (p = .033), respectively. However, High Apo‐B was not able to predict suboptimal TIMI flow. Accordingly, the Odds ratio was 0.56 (0.17–1.87), p = 0.349. The power of High LDL‐C and Non‐HDLC for prediction of MACE were assessed in distinct models. Attained odds ratios were [2.40 (0.90–6.36), p = .077] and [1.80 (0.75–4.35), p = 0.191], respectively.
Conclusion
Calculated Apo‐B appears to be a simple tool applicable for prediction of cardiovascular events in patients with STEMI superior to both Non‐HDLC and LDL‐C.</abstract><cop>New York</cop><pub>Wiley Periodicals, Inc</pub><pmid>33942349</pmid><doi>10.1002/clc.23610</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-5064-9623</orcidid><orcidid>https://orcid.org/0000-0003-0902-217X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0160-9289 |
| ispartof | Clinical cardiology (Mahwah, N.J.), 2021-06, Vol.44 (6), p.824-832 |
| issn | 0160-9289 1932-8737 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8207970 |
| source | Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Analysis Angioplasty Apo‐B Blood lipids Cardiac patients Cardiology Cardiovascular disease Care and treatment Cholesterol Clinical Investigations Clopidogrel Coronary vessels Heart attack Heart attacks Kidney diseases Lipoproteins Low density lipoproteins MACE Medical research Medical treatment Medicine, Experimental Normal distribution Patient outcomes Population primary PCI Prognosis revascularization Risk assessment STEMI survival Ticagrelor Transluminal angioplasty Values |
| title | Prognostic implications of calculated Apo‐lipoprotein B in patients with ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcome is tied to lower cut‐points |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T10%3A10%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20implications%20of%20calculated%20Apo%E2%80%90lipoprotein%20B%20in%20patients%20with%20ST%E2%80%90segment%20elevation%20myocardial%20infarction%20undergoing%20primary%20percutaneous%20coronary%20intervention:%20Outcome%20is%20tied%20to%20lower%20cut%E2%80%90points&rft.jtitle=Clinical%20cardiology%20(Mahwah,%20N.J.)&rft.au=Ghodsi,%20Saeed&rft.date=2021-06&rft.volume=44&rft.issue=6&rft.spage=824&rft.epage=832&rft.pages=824-832&rft.issn=0160-9289&rft.eissn=1932-8737&rft_id=info:doi/10.1002/clc.23610&rft_dat=%3Cgale_pubme%3EA710566738%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2541267103&rft_id=info:pmid/33942349&rft_galeid=A710566738&rfr_iscdi=true |